Natco Pharma is planning an aggressive capex in Andhra Pradesh, Telangana and Tamil Nadu. The company is setting up a formulations facility in the Pharma City in Visakhapatnam which will be ready by the end of next year. In addition, the company will be expanding research and development facility, chemical manufacturing facilities in Telangana and Tamil Nadu besides formulation facility in Hyderabad.
Recently, the company received approval from the Foreign Investment Promotion Board (FIPB) to raise up to Rs 450 crore by issuing securities to Qualified Institutional Buyers. It had also given nod to a proposal for increasing foreign investment limit from 24 percent to 31.5 percent of the paid up equity share capital of the company.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1676.00 |
| Dr. Reddys Lab | 1234.90 |
| Cipla | 1239.00 |
| Zydus Lifesciences | 947.70 |
| Lupin | 2332.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: